1. Home /
    2. Altai Protocol Library /
  2. New Drug: Sotorasib for k-ras G12C mutated NSCLC

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Drug: Sotorasib for k-ras G12C mutated NSCLC

New Drug: Sotorasib for k-ras G12C mutated NSCLC
Study:
  • Single-arm phase II study (CodeBreaK 100, phase II part)
  • Locally advanced or metastatic k-ras G12C mutant non-small cell lung cancer, progressed on anti-PD-1/PD-L1 and/or platinum-based combination chemotherapy AND targeted therapy if EGFR, ALK, ROS1 alterations were identified (N=126)
  • Sotorasib 960 mg PO daily
Efficacy:
  • ORR: 37.4% [28.8%-46.6%]
  • Median PFS: 6.7 mos [4.9 – 8.1 mos]
Safety:
  • Grade >=3 AEs: ALT increase (6%), AST increase (6%), diarrhea (4%)

J Thor Oncol 2021;16(3): s61

Li B, et al. Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More